Be the first person to write a business review for Phytopharm plc

Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel. Pluristem Therapeutics Inc., a development stage bio-therapeutics company, engages in the research, development, and production of placental-derived adherent stromal cells (ASCs). The company also involves in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of various severe degenerative, ischemic, and autoimmune disorders. It develops a pipeline of products that are derived from the human placenta, a non-controversial, non-embryonic, and adult stem cell source. These placental adherent stromal cells (ASCs) are expanded in the company’s proprietary PluriX three-dimensional bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. The company’s principal product under Phase I clinical trial is PLX-PAD for people suffering from peripheral artery disease. Its pre-clinical products include PLX-IBD for inflammatory bowel diseases; PLX-STROKE for ischemic strokes; PLX-BMT for bone marrow transplantation; and PLX-MS for multiple sclerosis. The company was formerly known as Pluristem Life Systems Inc. and changed its name to Pluristem Therapeutics Inc. in November 2007.

PML Microbiologicals, Inc. company was founded in 1969 and is headquartered in Wilsonville, Oregon. It has manufacturing facilities in Mississauga, Canada; and Portland, Oregon. As of December 8, 2008, PML Microbiologicals, Inc. operates as a subsidiary of BioMérieux S.A. PML Microbiologicals, Inc. manufactures culture media and microbiological products for clinical and industrial applications in North America. It offers prepared culture media, stains, reagents, quality control organisms, sterility products, and collection and transport systems, as well as accessories for microbiology laboratories. The company also provides custom products, such as minimum inhibitory concentration panels, parasitology kits, diluents, and rinsing fluids. It serves clinical, pharmaceutical, research, environmental, personal care, and food and beverage industries. PML Microbiologicals, Inc. was formerly known as Prepared Media Laboratory.

Poniard Pharmaceuticals was founded in 1984 and is headquartered in South San Francisco, California. Poniard Pharmaceuticals, Inc., together with its subsidiary, NeoRx Manufacturing Group, Inc., focuses on the development and commercialization of oncology products for people with cancer. Its lead platform product candidate, Picoplatin, is a platinum-based cancer therapy that is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Picoplatin is being studied in various cancer indications, combinations, and formulations. Poniard Pharmaceuticals is conducting a phase III clinical trial of intravenous picoplatin in small cell lung cancer; two phase II clinical trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers; and a clinical trial of oral picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in June 2006.

PRA International knows it takes more than laboratory research to get drugs approved. The company, a clinical research organization (CRO), provides an array of drug development services to pharmaceutical and biotech companies around the world. Services the company offers include clinical trials management, database development, and regulatory filings preparation. PRA's clients are engaged in most major therapeutic areas, but the firm's particular strengths lie in oncology, central nervous system disorders, cardiovascular disease, allergy and respiratory disorders, and infectious disease. The company is owned by private equity firm Genstar Capital.

Prana Biotechnology Limited (Prana) is a development-stage company at an early stage in the development of its pharmaceutical products that are designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses. Other potential applications for the Company’s therapies include Huntington’s disease, Parkinson’s disease, certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease) and age-related cataracts. The Company has two wholly owned subsidiaries, Prana Biotechnology Inc. and Prana Biotechnology UK Limited. Prana’s activities are focused within Australia and cover research into Alzheimer’s disease and other age-related degenerative disorders.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.